Results 131 to 140 of about 4,251 (181)

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors. [PDF]

Front Pharmacol
Zhang Y, Fu H, Kang X, Qiu Z, Yan H, He Q, Yang B, Xu Z, Luo P.   +8 more
europepmc   +1 more source

Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL. [PDF]

Leukemia
Mauro FR, Allsup D, Molica S.
europepmc   +1 more source

Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions. [PDF]

Leukemia
Tavarozzi R, Maher N, Catania G, Zacchi G, D'Andrea F, Sofia A, Zanni M, Ladetto M.   +7 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. [PDF]

Blood Adv
Ruan J, Bond DA, Shah B, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D, Xiang J, Hobbie B, Harbhajan M, Sahni TK, Chen GZ, Sigouros M, Inghirami G, Chen-Kiang S, Elemento O, Maddocks K, Leonard JP, Martin P.   +21 more
europepmc   +1 more source

The Brief Case: Cutaneous ulceration associated with acalabrutinib treatment

Journal of Clinical Microbiology
Victor Luzarraga, Céline Nourrisson, Florence Anglade, Carole Chevenet, Philippe Poirier, Maxime Moniot   +5 more
doaj   +1 more source

Updates in the management of newly diagnosed chronic lymphocytic leukemia. [PDF]

Hematology Am Soc Hematol Educ Program
McClellan K, Sitlinger A.
europepmc   +1 more source

Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature. [PDF]

Haematologica
Fazio M, Elena C, Ferrari J, Camilotto V, Stella S, Leotta D, Palumbo GA, Di Raimondo F, Romano A.   +8 more
europepmc   +1 more source

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. [PDF]

Cancer
Coste A, Sritharan N, Lok A, Tomowiak C, Ferrant E, Clavert A, Roos-Weil D, Bouclet F, Caillet A, Croizier C, Stocker N, Tchernonog E, Feugier P, Santagostino A, Hivert B, Michallet AS, De Guibert S, Lara D, Waultier-Rascalou A, Merabet F, Durand A, Bussot L, Laribi K, Dilhuydy MS, Lévy V, Quinquenel A.   +25 more
europepmc   +1 more source

Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. [PDF]

Blood Adv
Castonguay M, Anderson MA, Thompson P, Seymour JF.   +3 more
europepmc   +1 more source